Therapeutic approaches to metabolic syndrome (MetS) are numerous and may target
lipoproteins, blood pressure or anthropometric indices. Peroxisome proliferator-activated …

Abstract Purpose of Review Reduction of serum low-density lipoprotein cholesterol (LDL-C)
levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Non-alcoholic fatty liver disease (NAFLD) is a major health issue worldwide, frequently
associated with obesity and type 2 diabetes. Steatosis is the initial stage of the disease …

Homocysteine (Hcy) is an intermediate amino acid formed during the conversion from
methionine to cysteine. When the fasting plasma Hcy level is higher than 15 μmol/L, it is …

Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of
the nuclear hormone receptor superfamily, have been identified as key metabolic regulators …

Background and aims To assess the efficacy and safety of K-877 (Pemafibrate), a novel
selective peroxisome proliferator-activated receptor α modulator (SPPARMα) that possesses …

Background To overcome the concerns associated with the use of fibrates, pemafibrate (K-
877), a novel selective peroxisome proliferator-activated receptor modulator, was …

OBJECTIVE Type 2 diabetes is frequently complicated with atherogenic dyslipidemia. This
study aimed to evaluate the efficacy and safety of pemafibrate (K-877) in patients with type 2 …

In the era of precision medicine, treatments that target specific modifiable characteristics of
high-risk patients have the potential to lower further the residual risk of atherosclerotic …

The NR superfamily comprises 48 transcription factors in humans that control a plethora of
gene network programs involved in a wide range of physiologic processes. This review will …